51 – 100 of 135
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.
(
- Contribution to journal › Article
-
Mark
The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
(
- Contribution to journal › Article
-
Mark
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
(
- Contribution to journal › Article
-
Mark
Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
-
Mark
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
(
- Contribution to journal › Article
- 2010
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Utility-based outcomes made easy: The number needed per QALY gained (NNQ). Observational cohort study from Southern Sweden of TNF blockade in inflammatory arthritis.
(
- Contribution to journal › Article
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
-
Mark
Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease.
(
- Contribution to journal › Article
-
Mark
Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression.
(
- Contribution to journal › Article
-
Mark
Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.
(
- Contribution to journal › Article
-
Mark
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
(
- Contribution to journal › Article
- 2009
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults
(
- Contribution to journal › Published meeting abstract
-
Mark
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
(
- Contribution to journal › Article
-
Mark
Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Measures and time points relevant for post-surgical follow-up in patients with inflammatory arthritis: a pilot study
(
- Contribution to journal › Article
-
Mark
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
(
- Contribution to journal › Article
-
Mark
Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents
(
- Contribution to journal › Article
-
Mark
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register
(
- Contribution to journal › Article
-
Mark
Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Differences in Longitudinal Disease and Treatment Characteristics of Patients with Rheumatoid Arthritis Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article
- 2008
-
Mark
Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden
(
- Contribution to journal › Article
-
Mark
Health utilities improvement during TNF blockade in chronic arthritis occurs early in the treatment course, results from an eight year observational study in southern Sweden
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.552-552(
- Contribution to journal › Published meeting abstract
-
Mark
Why do women with early RA respond less well to MTX than men? Gender as a determinant of response in the initial phase of the Swefot trial
(
- Contribution to journal › Published meeting abstract
-
Mark
The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice
(
- Contribution to journal › Published meeting abstract
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
- 2007
-
Mark
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
(
- Contribution to journal › Article
-
Mark
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
(
- Contribution to journal › Article
-
Mark
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
(
- Contribution to journal › Article
-
Mark
Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation
(
- Contribution to journal › Article
-
Mark
Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
(
- Contribution to journal › Article
-
Mark
Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
- 2006
-
Mark
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Predictors of infusion reactions during infliximab treatment in patients with arthritis.
(
- Contribution to journal › Article
-
Mark
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
(
- Contribution to journal › Article
-
Mark
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
(
- Contribution to journal › Article
-
Mark
Swedish registers to examine drug safety and clinical issues in RA
(
- Contribution to journal › Scientific review
-
Mark
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Allvarlig lungsjukdom vid RA och TNF-blockering--finns det ett samband?
(
- Contribution to journal › Article
- 2005
-
Mark
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
-
Mark
No increase of severe infections in RA patients treated with TNF-blockers
2005) Annual European Congress of Rheumatology, 2005 In Annals of the Rheumatic Diseases 64(Suppl. 3). p.461-462(
- Contribution to journal › Published meeting abstract